
    this study was terminated early due to lack of efficacy based on the results of the week 48
    analysis as prespecified in the clinical study protocol.
  
['nonalcoholic steatohepatitis']
['sel', 'placebo to match sel 6 mg', 'placebo to match sel 18 mg']

        Key Inclusion Criteria:

          -  Liver biopsy consistent with NASH and cirrhosis (F4 fibrosis) according to the NASH
             Clinical Research Network (CRN) classification, in the opinion of the central reader

          -  Has the following laboratory parameters at the screening visit, as determined by the
             central laboratory:

               -  Alanine aminotransferase (ALT) ≤ 8 x upper limit of normal (ULN)

               -  Creatinine Clearance (CLcr) ≥ 30 milliliter/minute (mL/min), as calculated by the
                  Cockcroft-Gault equation

               -  HbA1c ≤ 9.5% (or serum fructosamine ≤ 381 micromole (μmol) if HbA1c is unable to
                  be resulted)

               -  International normalised ratio (INR) ≤ 1.4, unless due to therapeutic
                  anti-coagulation

               -  Platelet count ≥ 100,000/μL

        Key Exclusion Criteria:

          -  Prior history of decompensated liver disease including clinical ascites, hepatic
             encephalopathy (HE), or variceal bleeding

          -  Child-Pugh (CP) score > 7, as determined at screening, unless due to therapeutic
             anti-coagulation

          -  Model for End-stage Liver Disease (MELD) score > 12, as determined at screening,
             unless due to therapeutic anti-coagulation

          -  Other causes of liver disease including, but not limited to, alcoholic liver disease,
             hepatitis B, hepatitis C, autoimmune disorders, drug-induced hepatotoxicity, Wilson
             disease, iron overload, and alpha-1-antitrypsin deficiency, based on medical history
             and/or centralized review of liver histology.

          -  History of liver transplantation

          -  Current or history of hepatocellular carcinoma (HCC)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      